Raymond James Financial Services Advisors’s AYTU BioPharma AYTU Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6	Closed	-$7K	–	2823
2018 Q2	$7K	Buy	+6	New	+$10K	﹤0.01%	2757

Other funds holding AYTU

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AIM

Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Raymond James Financial Services Advisors's AYTU Position: Q3 2018 in Review

Raymond James Financial Services Advisors sold out of AYTU BioPharma (AYTU) in Q3 2018, closing a stake of 6 shares — an estimated $7K sold.

Raymond James Financial Services Advisors first reported a position in AYTU in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 8 funds tracked by Wall St. Rank hold AYTU as of Q3 2018.

Raymond James Financial Services Advisors reported no remaining AYTU BioPharma position as of Q3 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 6 AYTU BioPharma shares in Q3 2018, an estimated $7K.
Raymond James Financial Services Advisors first reported a position in AYTU BioPharma in Q2 2018 and held it in 1 quarter.
Raymond James Financial Services Advisors's AYTU BioPharma position peaked at $7K in Q2 2018.
8 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.